Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study

Sponsor
Henan Provincial People's Hospital
Study ID
NCT05532527
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy and safety of microwave ablation combined with Camrelizumab and chemotherapy in the treatment of patients with advanced non-small cell lung cancer.

Key Dates

Start date
Sep 20, 2022
Status verified
Sep 2022
Primary completion
Sep 20, 2023
Completion
Sep 20, 2025

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study group
    Microwave ablation combined with Camrelizumab and chemotherapy

Primary Outcome Measure

PFS [ Time Frame: Up to 24 months ]

Related Studies